Discovery of new pyridine-quinoline hybrids as competitive and non-competitive PIM-1 kinase inhibitors with apoptosis induction and caspase 3/7 activation capabilities

References

• Puente-Moncada N, Costales P, Antolin I, Nunez LE, Oro P, Hermosilla MA, Perez-Escuredo J, Rios-Lombardia N, Sanchez-Sanchez AM, Luno E, et al. Inhibition of FLT3 and PIM kinases by EC-70124 exerts potent activity in preclinical models of acute myeloid leukemia. Mol Cancer Ther. 2018;17(3):614–624.
   PubMed Web of Science ®Google Scholar
• Ogawa N, Yuki H, Tanaka A. Insights from PIM1 structure for anti-cancer drug design. Expert Opin Drug Discov. 2012;7(12):1177–1192.
   PubMed Web of Science ®Google Scholar
• Schenone S, Tintori C, Botta M. Using insights into PIM1 structure to design new anticancer drugs. Curr Pharm Des. 2010;16(35):3964–3978.
   PubMed Web of Science ®Google Scholar
• Blanco-Aparicio C, Carnero A. PIM kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol. 2013;85(5):629–643.
   PubMed Web of Science ®Google Scholar
• Mohamed EA, Ismail NSM, Hagras M, Refaat H. Medicinal attributes of pyridine scaffold as anticancer targeting agents. Futur J Pharm Sci. 2021;7(1):24.
   Web of Science ®Google Scholar
• Ye C, Zhang C, Huang H, Yang B, Xiao G, Kong D, Tian Q, Song Q, Song Y, Tan H, et al. The natural compound myricetin effectively represses the malignant progression of prostate cancer by inhibiting PIM1 and disrupting the PIM1/CXCR4 interaction. Cell Physiol Biochem. 2018;48(3):1230–1244.
   PubMedGoogle Scholar
• Liu K, Gao H, Wang Q, Wang L, Zhang B, Han Z, Chen X, Han M, Gao M. Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer. Cancer Sci. 2018;109(5):1369–1381.
   PubMed Web of Science ®Google Scholar
• Stafman LL, Mruthyunjayappa S, Waters AM, Garner EF, Aye JM, Stewart JE, Yoon KJ, Whelan K, Mroczek-Musulman E, Beierle EA. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. Oncotarget. 2018;9(32):22665–22679.
   PubMedGoogle Scholar
• Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016;22(11):1303–1313.
   PubMed Web of Science ®Google Scholar
• Abnous K, Manavi H, Mehri S, Alibolandi M, Kamali H, Ghandadi M, Hadizadeh F. In vitro evaluation of dihydropyridine-3-carbonitriles as potential cytotoxic agents through PIM-1 protein kinase inhibition. Res Pharm Sci. 2017;12(3):196–203.
   PubMedGoogle Scholar
• Walhekar V, Bagul C, Kumar D, Muthal A, Achaiah G, Kulkarni R. Topical advances in PIM kinases and their inhibitors: medicinal chemistry perspectives. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188725.
   PubMed Web of Science ®Google Scholar
• Mori M, Tintori C, Christopher RS, Radi M, Schenone S, Musumeci F, Brullo C, Sanita P, Delle Monache S, Angelucci A, et al. A combination strategy to inhibit PIM-1: synergism between noncompetitive and ATP-competitive inhibitors. ChemMedChem. 2013;8(3):484–496.
   PubMed Web of Science ®Google Scholar
• Morwick T. PIM kinase inhibitors: a survey of the patent literature. Expert Opin Ther Pat. 2010;20(2):193–212.
   PubMed Web of Science ®Google Scholar
• Nair JR, Caserta J, Belko K, Howell T, Fetterly G, Baldino C, Lee KP. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma. Leukemia. 2017;31(8):1715–1726.
   PubMed Web of Science ®Google Scholar
• Wähler K, Kräling K, Steuber H, Meggers E. Non-ATP-mimetic organometallic protein kinase inhibitor. ChemistryOpen. 2013;2(5-6):180–185.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Han B-G, Cho J-W, Choi J-S, Lee J, Song H-J, Koh JS, Lee BI. Crystal structure of PIM1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode. PLos One. 2013;8(7):1–7.
   Web of Science ®Google Scholar
• Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, Kondo S, Wang H, Wang H, Yeung S-CJ, et al. Hypoxia-mediated up-regulation of PIM-1 contributes to solid tumor formation. Am J Pathol. 2009;175(1):400–411.
   PubMed Web of Science ®Google Scholar
• Cheney IW, Yan S, Appleby T, Walker H, Vo T, Yao N, Hamatake R, Hong Z, Wu JZ. Identification and structure-activity relationships of substituted pyridones as inhibitors of PIM-1 kinase. Bioorg Med Chem Lett. 2007;17(6):1679–1683.
   PubMed Web of Science ®Google Scholar
• Li K, Li Y, Zhou D, Fan Y, Guo H, Ma T, Wen J, Liu D, Zhao L. Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and PIM-1 kinase inhibitors. Bioorg Med Chem. 2016;24(8):1889–1897.
   PubMed Web of Science ®Google Scholar
• Swellmeen L, Shahin R, Al-Hiari Y, Alamiri A, Hasan A, Shaheen O. Structure based drug design of PIM-1 kinase followed by pharmacophore guided synthesis of quinolone-based inhibitors. Bioorg Med Chem. 2017;25(17):4855–4875.
   PubMed Web of Science ®Google Scholar
• Abdelaziz ME, El-Miligy MMM, Fahmy SM, Mahran MA, Hazzaa AA. Design, synthesis and docking study of pyridine and thieno[2,3-b] pyridine derivatives as anticancer PIM-1 kinase inhibitors. Bioorg Chem. 2018;(80):674–692.
   PubMed Web of Science ®Google Scholar
• Howard JC. 2-amino-3-nitrotoluene. Org Synth. 1955:42–44.
   Google Scholar
• JJaS B. Synthesis of novel substituted quinoline derivatives with 2-amino-5-methylthiophene-3-carbonitrile. Indo Am J Pharm Res. 2014; 45(5):2496–2502.
   Google Scholar
• Hamama WS, Ibrahim ME, Gooda AA, Zoorob HH. Recent advances in the chemistry of 2-chloroquinoline-3-carbaldehyde and related analogs. RSC Adv. 2018;8(16):8484–8515.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab BF, Khidre RE. 2-chloroquinoline-3-carbaldehyde II: synthesis, reactions, and applications. J Chem. 2013;2013:1–13.
   Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55–63.
   PubMed Web of Science ®Google Scholar
• Xu T, Niu C, Zhang X, Dong M. β-Ecdysterone protects SH-SY5Y cells against β-amyloid-induced apoptosis via c-Jun N-terminal kinase- and Akt-associated complementary pathways. Lab Invest. 2018;98(4):489–499.
   PubMed Web of Science ®Google Scholar
• Brown AM. A new software for carrying out one-way ANOVA post hoc tests. Comput Methods Programs Biomed. 2005;79(1):89–95.
   PubMed Web of Science ®Google Scholar
• Available from: www.promega.com
   Google Scholar
• Ishchenko A, Zhang L, Le Brazidec J-Y, Fan J, Chong JH, Hingway A, Raditsis A, Singh L, Elenbaas B, Hong VS, et al. Structure-based design of low-nanomolar PIM kinase inhibitors. Bioorg Med Chem Lett. 2015;25(3):474–480.
   PubMed Web of Science ®Google Scholar
• McGann M. Fred pose prediction and virtual screening accuracy. J Chem Inf Model. 2011;51(3):578–596.
   PubMed Web of Science ®Google Scholar
• McGann M. Fred and hybrid docking performance on standardized datasets. J Comput Aided Mol Des. 2012;26(8):897–906.
   PubMed Web of Science ®Google Scholar
• Andre CM, Hausman J-F, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19.
   PubMed Web of Science ®Google Scholar
• Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT. Conformer generation with omega: algorithm and validation using high quality structures from the protein databank and Cambridge structural database. J Chem Inf Model. 2010;50(4):572–584.
   PubMed Web of Science ®Google Scholar
• Pazouki L, Niinemets Ü. Multi-substrate terpene synthases: their occurrence and physiological significance. Front Plant Sci. 2016;7:1019.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. Swissadme: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458–1461.
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Keseru GM, Leeson PD, Rees DC, Reynolds CH. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014;13(2):105–121.
   PubMed Web of Science ®Google Scholar
• Daina A, Zoete V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117–1121.
   PubMed Web of Science ®Google Scholar
• Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today. 2008;13(9-10):379–393.
   PubMed Web of Science ®Google Scholar
• Cheng T, Zhao Y, Li X, Lin F, Xu Y, Zhang X, Li Y, Wang R, Lai L. Computation of octanol-water partition coefficients by guiding an additive model with knowledge. J Chem Inf Model. 2007;47(6):2140–2148.
   PubMed Web of Science ®Google Scholar
• Farghaly A-R. Synthesis, reactions and antimicrobial activity of some new indolyl-1,3,4-oxadiazole, triazole and pyrazole derivatives. J Chin Chem Soc. 2004;51(1):147–156.
   Web of Science ®Google Scholar
• Di L. The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol. 2014;10(3):379–393.
   PubMed Web of Science ®Google Scholar
• Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev. 2002;34(1-2):17–35.
   PubMed Web of Science ®Google Scholar
• Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48(6):662–670.
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (pains) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53(7):2719–2740.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–2623.
   PubMed Web of Science ®Google Scholar